2025-01-17 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Report

**1. Performance vs. S&P 500 (VOO):**

Vertex Pharmaceuticals Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative medicines.

The cumulative return of VRTX is 137.01%, significantly outperforming the S&P 500 (VOO) which has a cumulative return of 116.43%.  The difference is 20.58 percentage points.  The provided relative divergence of 54.2% indicates that this outperformance is in the upper 54.2% percentile of historical performance relative to the S&P 500.  The alpha consistently remains around 0.1, suggesting consistent outperformance relative to the market, though the beta of approximately 0.1 indicates low correlation to the market movements.

**Alpha and Beta Analysis:**  The provided data shows varying CAGR (Compound Annual Growth Rate) and Maximum Drawdown (MDD) figures across different periods.  While the CAGR demonstrates periods of strong growth, the MDD highlights significant risk associated with the investment. The consistently low beta across periods suggests limited correlation with the overall market.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 38.0% | 29.1% | 12.0% | 0.1 | 107.0 |
| 2016-2018  | 39.0% | 29.1% | 25.0% | 0.1 | 107.0 |
| 2017-2019  | 99.0% | 18.8% | 67.0% | 0.1 | 107.0 |
| 2018-2020  | 30.0% | 30.2% | -3.0% | 0.1 | 107.0 |
| 2019-2021  | 14.0% | 33.8% | -66.0% | 0.1 | 107.0 |
| 2020-2022  | 16.0% | 33.8% | 9.0% | 0.1 | 107.0 |
| 2021-2023  | 84.0% | 20.6% | 60.0% | 0.1 | 107.0 |
| 2022-2024  | 78.0% | 23.0% | 56.0% | 0.1 | 107.0 |
| 2023-2025  | 53.0% | 23.0% | -15.0% | 0.1 | 107.0 |


**2. Recent Price Movement:**

* **Closing Price:** $417.01
* **Last Market Price:** $417.03
* **5-Day Moving Average:** $415.17
* **20-Day Moving Average:** $412.86
* **60-Day Moving Average:** $452.76

The stock price is currently trading below its 5, 20, and 60-day moving averages, suggesting a potential downward trend.  The significant difference between the current price and the 60-day average highlights this downward pressure.

**3. Technical Indicators:**

* **RSI:** 56.93 (Slightly above neutral; neither overbought nor oversold)
* **PPO:** 0.76 (Positive, suggesting upward momentum)
* **20-Day Relative Divergence Change:** +1.2 (Short-term upward trend)
* **Expected Return (2+ years):** 27.8%  (This represents the expected excess return over the S&P 500 for long-term investment.)

Given that the current market price of $417.03 is not significantly different from the recent closing price, no immediate extreme price changes (sharp increase or decrease) are apparent.  The indicators suggest a moderate bullish sentiment, but the price being below its moving averages warrants caution.

**4. Recent Earnings Analysis:**

The earnings data shows significant volatility.  There's a large negative EPS in August 2024, which needs further investigation to understand the underlying cause.  Otherwise, the company shows generally positive EPS and steady revenue growth.

| Date       | EPS      | Revenue      |
|------------|----------|--------------|
| 2024-11-05 | $4.05    | $2.77B       |
| 2024-08-02 | -$13.92  | $2.65B       |
| 2024-05-07 | $4.26    | $2.69B       |
| 2023-11-07 | $4.01    | $2.48B       |
| 2024-11-05 | $4.01    | $2.48B       | *(Duplicate entry, likely a data error)*


**5. Financial Information:**

**Revenue and Profitability:**  Revenue is relatively consistent, showing a modest increase over time. Profit margins remain impressively high, consistently above 85%.

| Quarter     | Revenue   | Profit Margin |
|-------------|-----------|---------------|
| 2024-09-30  | $2.77B    | 85.84%        |
| 2024-06-30  | $2.65B    | 85.94%        |
| 2024-03-31  | $2.69B    | 87.27%        |
| 2023-12-31  | $2.52B    | 85.38%        |
| 2023-09-30  | $2.48B    | 87.17%        |

**Capital and Profitability:** Equity shows some fluctuation, and the ROE (Return on Equity) exhibits significant volatility, including a large negative value in Q2 2024, which requires further analysis.

| Quarter     | Equity     | ROE      |
|-------------|------------|----------|
| 2024-09-30  | $15.63B    | 6.69%    |
| 2024-06-30  | $14.77B    | -24.32%  |
| 2024-03-31  | $18.55B    | 5.93%    |
| 2023-12-31  | $17.58B    | 5.51%    |
| 2023-09-30  | $16.51B    | 6.27%    |


**7. Overall Analysis:**

VRTX has shown strong historical performance, significantly outperforming the S&P 500.  However, recent price action indicates a potential downward trend, despite positive technical indicators (PPO and relative divergence). The large negative EPS in Q2 2024 and the volatile ROE warrant further investigation into the company's financial health. While the long-term outlook (2+ years) suggests a significant potential excess return over the S&P 500, investors should carefully consider the recent volatility and conduct thorough due diligence before making any investment decisions.  The exceptionally high profit margins are a positive sign, but understanding the reasons behind the fluctuations in EPS and ROE is crucial.


**8. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  Investing involves risk, including the potential loss of principal.  Always conduct thorough research and consider seeking professional financial advice before making any investment decisions.
